Jatt Ii Acquisition Corp · NASDAQ:JATT
Jatt Ii Acquisition — SPAC Merger (June 2026)
23 slides from Jatt Ii Acquisition's SPAC merger presentation, Jun 29, 2026
Slide 1: Corporate Presentation June 2026
Exhibit 99.2 Corporate Presentation June 2026
Slide 2: Disclaimer and forward-looking statements
Disclaimer and forward-looking statements This confidential presentation has been made available to you for informal purposes only with the consent of Talawar Tx Inc. (the “Company” or Talawar ) and JATT II Acquisition Corp (“JATT”) and has been prepared to assist interested parties in making their
Slide 3: Risk factors (1/2)
Risk factors (1/2) The below list of risk factors has been prepared solely for purposes of the proposed private placement transaction (the “Private Placement”) as part of the proposed business combination of JATT and Talawar (the “Business Combination”), and solely for potential investors in the Pri
Slide 4: Risk factors (2/2)
Risk factors (2/2) Risks Related to the Private Placement Capital Raise. There can be no assurance that the amount of funds raised in the Private Placement will be sufficient for use by the combinedc ompany following the Business Combination (the “Combined Company”). Voting Power. The issuance of sh
Slide 5: Our steadfast commitment to those suffering from I&I disorders
Our steadfast commitment to those suffering from I&I disorders: We are developing meaningful therapies purpose-built to To improve lives by smash through the current dramatically monotherapy efficacy plateau broadening and deepening responses by leveraging the power and for patients precision of bis
Slide 6: Talawar is led by a team of highly experienced drug developers
Talawar is led by a team of highly experienced drug developers with deep expertise in I&I Management Team Board of Directors Dan Becker, MD, PhD Christine Borowski, PhD Someit Sidhu, MD Evan Taddeo Marc Schegerin Fabio Nunes Kristine Callahan MD, MBA MD, MMSc PhD CPA Chief Medical Officer VP, Corpor
Slide 7: Talawar aims to develop best-in-class bispecifics for I&I diseases
Talawar aims to develop best-in-class bispecifics for I&I diseases Combinations in I&I diseases can TALA-125 combines IL-13 and IL-18 break the monotherapy efficacy inhibition: two orthogonal, 1 ceiling; doing this in AD may expand validated mechanisms of action the largest future I&I market TALA-12
Slide 8: Talawar's pipeline is powered by thoughtful design, beginning in Atopic Dermatitis
Talawar's pipeline is powered by thoughtful design for transformative impact, beginning in Atopic Dermatitis 1 Novel IP composition of matter beyond 2045 Program Discovery IND-enabling Clinical Ph1 start 1Q27 Anti-IL-13 x IL-18 bispecific Ph1 readout 4Q27 TALA-125 Atopic Dermatitis, Ph2b start 1Q28
Slide 9: Combination approaches can break through the monotherapy efficacy ceiling
Combination approaches can break through the monotherapy efficacy ceiling in I&I disorders Ulcerative Colitis Crohn’s Disease Psoriatic Arthritis Atopic Dermatitis 100% 100% 100% 100% ? 47% 50% 50% 50% Aletekitug 50% 44% 42% 39% 33% - 42% 29% 25% 24% 22% 21% 21% 0% 0% 0% 0% Anti-TNFα Anti-IL-23 Anti
Slide 10: Combining IL-13 and IL-18 inhibition for clinical benefits in Atopic Dermatitis
We believe combining IL-13 and IL-18 inhibition will lead to significant clinical benefits in Atopic Dermatitis IL-13 mAbs are IL-18 IL-18 current standard inhibition inhibition of care, and IL-18 has potential to may improve itch mAbs are expand the independently recently de- addressable from Th2 r
Slide 11: IL-13 and IL-18 are well-validated targets in atopic dermatitis
1 IL-13 and IL-18 are well-validated targets in atopic dermatitis 2 3 IL-13 Programs IL-18 Programs 35% 30% 28% 23% 27% 22% 16% vIGA-AD 0/1 15% 12% (Pbo-Adjusted) 12% 9% Company Eli Lilly Regeneron / Sanofi Leo Pharma Apogee GSK Novartis Evommune Program Ebglyss Dupixent Adbry Zumilokibart Aletekitu
Slide 12: TALA-125 is a potentially best-in-class IL-13 x IL-18 bispecific
TALA-125 is a potentially best-in- class IL-13 x IL-18 bispecific TALA-125 leverages the validated lebrikizumab epitope TALA-125’s IL-18 binding arm binds the same epitope as aletekitug, which spares IL-37-mediated anti- 1 inflammatory activity TALA-125 demonstrates affinity and potency in-line with
Slide 13: IL-18 inhibition could drive efficacy in dupilumab-refractory patients
IL-18 inhibition could potentially drive clinical efficacy in dupilumab-refractory patients Aletekitug shows meaningful Higher baseline IL-18 levels IL-18 remains elevated in AD skin 1 clinical response in Dupi-IR correlate to poor dupilumab post-dupilumab and increases in 2 patients at 12 weeks res
Slide 14: Targeting IL-13 and IL-18 mitigates itch via two independent pathways
Targeting IL-13 and IL-18 mitigates itch via two independent 1 pathways (Th2 and non-Th2) Anti-IL-18 shows similar IL-18 KO addresses Th2- IL-13 x IL-18 could deliver effect on itch to Nemluvio independent itch synergistic effects on itch 0 600 - 0.5 Th2-dependent 500 pathway 400 IL-13 -1.5 300 200
Slide 15: TALA-125 utilizes the well-validated lebrikizumab epitope
TALA-125 utilizes the well-validated lebrikizumab epitope, preserving natural IL-13 regulation 1 TALA-125 & Lebrikizumab Target Same Epitope Key Advantages of TALA-125 Lebrikizumab & TALA-125 Tralokinumab Like lebrikizumab, TALA-125 prevents IL-13 signaling via IL-4R but maintains binding to IL-13Rα
Slide 16: TALA-125 neutralizes IL-18 without interfering with IL-37 activity
TALA-125 neutralizes IL-18 without interfering with IL-37- 1 mediated anti-inflammatory activity CMK389 (Novartis) & Aletekitug (GSK) & Camoteskimab (Apollo) Key Advantages of TALA-125 TALA-125 IL-37 IL-18 IL-18BP Regulatory MOA Avoids displacing the natural IL-18 inhibitor IL-18BP, IL-18 IL-18BP 2
Slide 17: TALA-125 has comparable affinity and potency with promising developability
TALA-125 has comparable affinity and potency to anti-IL-13 and anti-IL-18, with a promising developability profile Comparable Affinity and Potency to 1 2 Best-in-Class Reference Binders Promising Developability Profile Method Antibody IL-13 (pM) IL-18 (pM) High expression titer (currently at 10g/L)
Slide 18: TALA-125 utilizes well-validated half-life extension
TALA-125 utilizes well-validated half-life extension, with an expected human half-life of ~60 to 90 days TALA-125 has a ~1.55x fold increase in … which is expected to support extended 1 3 NHP half-life vs. lebrikizumab … dosing intervals in humans Human: Implied '125 NHP ratio human half-life 3.5x ~
Slide 19: TALA-125 projected to suppress IL-13 in line with monotherapies
TALA-125 is projected to suppress IL-13 in line with monotherapies, with IL-18 inhibition beyond aletekitug IL-13 suppression in induction designed to IL-18 suppression designed to match or 1 2 match lebrikizumab / zumilokibart exceed aletekitug Phase 2a dose Potential TALA-125 Potential TALA-125 In
Slide 20: Efficient path to clinical proof-of-concept and potential value inflection
Efficient path to clinical proof-of-concept and potential value inflection for TALA-125 2027 2028 2029 Interim Ph1 Ph2b Ph2b HV data 16wk data 28wk data Key Milestones Safety, PK, half-life Induction-phase Durability of extension efficacy response Ph1 HV SAD n=56 Clinical Development Ph1 HV MAD Ph2b
Slide 21: Transaction Overview
Transaction Overview Pro forma valuation and ownership Transaction Overview Sources of Funds • JATT II Acquisition Corp. to combine with Talawar Tx at an implied Talawar Rollover Equity $120.0 $120.0M pre-money equity value PIPE 225.0 • $225.0M PIPE Cash in Trust 60.0 1 • $60.0M in trust account Spo
Slide 22: TALA-125 Addresses De-risked Targets
TALA-125 Addresses De-risked Targets • Combines two validated mechanisms in AD, with potential to vastly broaden and deepen clinical responses • Rationally designed for optimal developability, high potency and extended human half-life • Efficient path to value inflection enabled by validated targets
Slide 23: Thank you
Thank you admin@talawartx.com